Study S003266

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of VCT220 in Participants With Hypertension and Obesity or Overweight.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07360275
Acronym: VICTOR-HTN
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 160
Start: 2026-03-01
Primary completion: 2026-10-30
Lead sponsor: Vincentage Pharma Co., Ltd
Conditions: Hypertension
Interventions: DRUG:VCT220 Tablet; DRUG:VCT220 Placebo Tablet
Results posted: FALSE

Registered primary outcomes

Change from baseline in office seated systolic blood pressure (SBP) at Week 20 [From baseline to week 20]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.